Tashatuvango / Shutterstock.com
The English High Court has rejected Pfizer’s attempt to amend a patent that was ruled partially invalid in its long-standing dispute with generics companies Mylan and Allergan.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Warner-Lambert; Pfizer; Mylan; English High Court; Lyrica; neuropathic pain; Allergan
